Industry News
Biotechnology Industry News
Chutes & Ladders—Califf returns to FDA after narrow Senate confirmation
Chutes & Ladders—Califf returns to FDA after narrow Senate confirmation klahucik Wed, 02/16/2022 - 14:14
NIAID vaccine R&D director who collaborated with Moderna on COVID-19 vaccine to retire
NIAID vaccine R&D director who collaborated with Moderna on COVID-19 vaccine to retire mbayer Wed, 02/16/2022 - 12:43
Gilead comes back around on Hookipa HIV partnership, signing away $15M upfront and more down the line
Gilead comes back around on Hookipa HIV partnership, signing away $15M upfront and more down the line klahucik Wed, 02/16/2022 - 09:49
Sage, Biogen score on phase 3 depression trial, but we still don’t know about durability
Sage, Biogen score on phase 3 depression trial, but we still don't know about durability aarmstrong Wed, 02/16/2022 - 09:27
Mirati’s ‘very big’ KRAS drug gets December decision date, further extending Lumakras’ first-mover status
Mirati's 'very big' KRAS drug gets December decision date, further extending Lumakras' first-mover status klahucik Wed, 02/16/2022 - 08:52
After a year as Merck KGaA healthcare CEO, Guenter reflects on I-O bispecific flop, spots new multiple sclerosis strategy
After a year as Merck KGaA healthcare CEO, Guenter reflects on I-O bispecific flop, spots new multiple sclerosis strategy aliu Wed, 02/16/2022 - 06:03
Third Harmonic Bio raises $105M in series B to push hives treatment through phase 1b
Third Harmonic Bio raises $105M in series B to push hives treatment through phase 1b mbayer Tue, 02/15/2022 - 16:24
Single-asset Equillium buys Bioniz for up to $329M, adding 3 drugs to its pipeline
Single-asset Equillium buys Bioniz for up to $329M, adding 3 drugs to its pipeline klahucik Tue, 02/15/2022 - 14:54
Electra, one of 2 Star biotechs, snags $84M to apply brakes to ‘immune system haywire’
Electra, one of 2 Star biotechs, snags $84M to apply brakes to 'immune system haywire' klahucik Tue, 02/15/2022 - 13:53
Cytokinetics drug fails late-stage trial testing exercise capacity, as FDA considers nod in heart failure
Cytokinetics drug fails late-stage trial testing exercise capacity, as FDA considers nod in heart failure klahucik Tue, 02/15/2022 - 12:59
Biotech pipeline is outpaced by antibacterial resistance, new BIO report says
Biotech pipeline is outpaced by antibacterial resistance, new BIO report says mbayer Tue, 02/15/2022 - 12:18
Merck gets ahead of the Curve, inking oncology and neurology drug discovery deal with emerging British biotech
Merck gets ahead of the Curve, inking oncology and neurology drug discovery deal with emerging British biotech ntaylor Tue, 02/15/2022 - 12:15
UCB, Novartis and more pile into SpliceBio series A, ponying up $57M to tackle a big barrier to gene therapy
UCB, Novartis and more pile into SpliceBio series A, ponying up $57M to tackle a big barrier to gene therapy ntaylor Tue, 02/15/2022 - 12:06
A new SPAC decides to enter murky waters to hunt for biotechs in downsized $75M IPO
A new SPAC decides to enter murky waters to hunt for biotechs in downsized $75M IPO klahucik Tue, 02/15/2022 - 11:22
IQVIA sees 2021 revenues jump 22% led by strong service growth
IQVIA sees 2021 revenues jump 22% led by strong service growth mbayer Tue, 02/15/2022 - 09:58
Larimar kept in limbo as FDA maintains clinical hold on leading candidate
Larimar kept in limbo as FDA maintains clinical hold on leading candidate mbayer Tue, 02/15/2022 - 09:21
Legend’s early-stage CAR-T on FDA hold after single patient dosed
Legend's early-stage CAR-T on FDA hold after single patient dosed aarmstrong Tue, 02/15/2022 - 08:56
Intellia-ONK ink up to $920M pact for 5 CRISPR-edited cancer cell therapies
Intellia-ONK ink up to $920M pact for 5 CRISPR-edited cancer cell therapies klahucik Tue, 02/15/2022 - 08:47
AC Immune’s Janssen-partnered Alzheimer’s vaccine spurs tau-attacking antibodies in early-stage trial
AC Immune's Janssen-partnered Alzheimer's vaccine spurs tau-attacking antibodies in early-stage trial aarmstrong Tue, 02/15/2022 - 08:36
Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end
Lilly reunites with ImmunoGen to expand into ADCs, paying $13M upfront and $1.7B on the back end ntaylor Tue, 02/15/2022 - 07:57